ALX ONCOLOGY HOLDINGS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Phone
650-466-7125
Fiscal Year End
1231
EIN
850642577
Financial Overview
FY2025
$147.78M
Total Assets
$263.46M
Stockholders' Equity
$-1.90
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 10-K Annual financial report | March 9, 2026 | View on SEC |
| 3 Initial insider ownership report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 9, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
Annual Reports
10-K
March 9, 2026
- Lead drug candidate, evorpacept, is a CD47 blocker undergoing multiple Phase 2 and Phase 3 clinical trials for advanced cancers.
- ALXO held $125.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing a cash runway into late 2026.
Insider Trading
BUY
3 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.